Back

A randomized, placebo-controlled phase 3 study of plozasiran in patients with familial chylomicronemia syndrome: PALISADE - 1 year open label extension

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: Cardiovascular disease in primary care Cardiovascular Disease in Primary Care ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Professor Gerald Watts

University of Western Australia, Perth (Australia)

4 More presentations in this session

Presentation thumbnail
Atrial cardiomyopathy in the electrocardiogram: the prognostic value of p-wave abnormalities in a primary care population
Doctor G. Paixao (Belo Horizonte, BR)
Abstract Slides Video
Presentation thumbnail
Using primary and routinely collected data to determine the prevalence of cardiovascular-kidney-metabolic syndrome in rural China
Professor M. Tian (Harbin, CN)
Abstract Slides Video
Presentation thumbnail
Impact of changes in serum uric acid levels on clinical outcomes in patients with asymptomatic hyperuricemia
Doctor K. Matsui (Kumamoto, JP)
Abstract Slides Video
Presentation thumbnail
PCSK9 and ANGPTL3 inhibitors in homozygous familial hypercholesterolemia: a meta-analysis of randomized clinical trials
Assistant Professor I. Bytyci (Pristina, XK)
Abstract Slides Video

Access the full session

Session thumbnail
Cardiovascular disease in primary care

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources